These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 2667448

  • 1. Tumour markers in pancreatic cancer.
    Haglund C, Kuusela P, Roberts PJ.
    Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
    [Abstract] [Full Text] [Related]

  • 2. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [Abstract] [Full Text] [Related]

  • 3. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [Abstract] [Full Text] [Related]

  • 4. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I.
    Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
    [Abstract] [Full Text] [Related]

  • 5. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
    Safi F, Roscher R, Beger HG.
    Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K.
    Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
    [Abstract] [Full Text] [Related]

  • 7. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA, Kauppinen R, Eskelinen M, Partanen K, Pikkarainen P, Alhava E.
    Anticancer Res; 1993 Aug; 13(3):763-8. PubMed ID: 8317910
    [Abstract] [Full Text] [Related]

  • 8. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C.
    Anticancer Res; 2002 Aug; 22(4):2311-6. PubMed ID: 12174919
    [Abstract] [Full Text] [Related]

  • 9. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Aug; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 10. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G, Manabe T, Watanabe Y, Endo K, Kudo H, Suzuki T, Tobe T.
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [Abstract] [Full Text] [Related]

  • 11. [Tumor markers of pancreatic cancer].
    Takami H, Hishinuma S, Shintoku J, Furuuchi T, Ogata Y, Abe O.
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
    [Abstract] [Full Text] [Related]

  • 12. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
    Chen YF, Mai CR, Tie ZJ, Feng ZT, Zhang J, Lu XH, Lu GJ, Xue YH, Pan GZ.
    Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
    [Abstract] [Full Text] [Related]

  • 13. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S.
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
    Röthlin M, Metzger U, Joller H, Largiadèr F.
    Schweiz Med Wochenschr; 1988 Jun 18; 118(24):924-9. PubMed ID: 2456610
    [Abstract] [Full Text] [Related]

  • 16. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
    Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM.
    Cancer Res; 1988 Mar 15; 48(6):1435-8. PubMed ID: 3162196
    [Abstract] [Full Text] [Related]

  • 17. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar 15; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 18. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
    Chen YF.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun 15; 11(3):229-31. PubMed ID: 2529993
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.